1-5 of 5
Chung-Wai Shiau
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B54: Type II interleukin 1 receptor-modulated SET/PP2A/p-ERK signaling is associated with regorafenib resistance in human colorectal cancer cells

Ai-Chung Mar, Chun-Ho Chu, Shung-Haur Yang, Jeng-Kai Jiang, Chung-Wai Shiau, Te-Chang Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B54.
https://doi.org/10.1158/1535-7163.TARG-15-B54
Published: 01 December 2015
View article titled, Abstract B54: Type II interleukin 1 receptor-modulated SET/PP2A/p-ERK signaling is associated with regorafenib resistance in human colorectal cancer cells
Journal Articles

SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model

Wei-Tien Tai, Chung-Wai Shiau, Yong-Shi Li, Yao-Li Chen, Pei-Yi Chu, Jui-Wen Huang, Cheng-Yi Hsu, Yi-Chieh Hsu, Pei-Jer Chen, Kuen-Feng Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (1): 27–36.
https://doi.org/10.1158/1535-7163.MCT-13-0595
Published: 13 January 2014
View article titled, SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model
Open the PDF for SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti–Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model in another window
Includes: Supplementary data
Journal Articles

Abstract C185: CIP2A is a novel therapeutic target for an erlotinib derivative in EGFR wild-type NSCLC cells.

Ting-Ting Chao, Cheng Yi Wang, Fang-Yu Chang, Yen-Lin Chen, Chung-Wai Shiau, Kuen-Feng Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C185.
https://doi.org/10.1158/1535-7163.TARG-13-C185
Published: 01 November 2013
View article titled, Abstract C185: CIP2A is a novel therapeutic target for an erlotinib derivative in EGFR wild-type NSCLC cells.
Journal Articles

Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3

Wei-Tien Tai, Ann-Lii Cheng, Chung-Wai Shiau, Chun-Yu Liu, Ching-Huai Ko, Mai-Wei Lin, Pei-Jer Chen, Kuen-Feng Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 452–463.
https://doi.org/10.1158/1535-7163.MCT-11-0412
Published: 08 February 2012
View article titled, Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3
Open the PDF for Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3 in another window
Journal Articles

Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins

Dayong Zhai, Chaofang Jin, Chung-wai Shiau, Shinichi Kitada, Arnold C. Satterthwait, John C. Reed
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (6): 1639–1646.
https://doi.org/10.1158/1535-7163.MCT-07-2373
Published: 19 June 2008
View article titled, Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins
Open the PDF for Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins in another window
Includes: Supplementary data